Anti-Nuclear Mitotic Apparatus Protein (NuMA), Monoclonal Antibody
| Product Name | Anti-Nuclear Mitotic Apparatus Protein (NuMA), Monoclonal Antibody |
|---|---|
| Description | Recognizes a phosphorylated protein of 228kDa, identified as nuclear mitotic apparatus protein (NuMA). Its epitope is resistant to phosphatases. NuMA is intra-nuclear protein and present in nucleus during interphase. At the onset of mitosis, it redistributes from the nucleus to two centrosomal structures that later will become part of the mitotic spindle pole. After anaphase, the protein redistributes from the spindle polar region into reforming nucleus. NuMA is an essential protein during mitosis for the terminal phases of chromosome separation and/or nuclear reassembly. Recently a study shows that NuMA is cleaved to a 180 to 200kDa during apoptosis. Chromosomal translocation of this gene with the RARA (retinoic acid receptor, alpha) gene on chromosome 17 has been detected in patients with acute promyelocytic leukemia. |
| Synonyms | Nuclear Mitotic Apparatus Protein 1, NuMA protein, NUMA1, SP-H antigen, Structural nuclear protein, |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | A73-B/D12 |
| Immunogen | Colon carcinoma 174T cells |
| Isotype | IgM, kappa |
| Reactivity | Human |
| Applications | FC, IF, IHC |
| Form | 200ug/ml of Ab purified from Bioreactor Concentrate. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml. |
| Gene Id | 4926 |
| Uniprot | Q14980 |
| Storage | Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required. |
| References | Butschak G et al. New monoclonal antibodies recognizing phosphorylated proteins in mitotic cells. Acta Histochem 1995, 97(1):19-31Compton DA and Cleveland DW. NuMA is required for the proper completion of mitosis. J Cell Biol 1993, 120(4):947-57Price CM and Pettijohn DE. Redistribution of the nuclear mitotic apparatus protein (NuMA) during mitosis and nuclear assembly. Properties of purified NuMA protein. Exp Cell Res 1986, 166:295-311.Gueth-Hallonet C et al. Cleavage of the nuclear matrix protein NuMA during apoptosis. Exp Cell Res 1997, 233(1):21-24 |
| Supplier | ARP |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
